Pibrentasvir(CAS: 1353900-92-1)

Pibrentasvir is a crystalline compound with a molecular weight of approximately 498.54 g/mol. It has a solubility of about 0.1 mg/mL in water. Chemically, it is not highly reactive under normal conditions but can undergo oxidation under acidic or alkaline conditions. Its melting point is around 220-225°C.

Pibrentasvir is typically synthesized through a multi-step organic synthesis process. The key steps involve protecting group chemistry, coupling reactions, and ring formation. The synthesis is carried out using standard organic solvents and catalysts. The overall yield is around 60% to 70%.

Pibrentasvir is primarily used in the pharmaceutical industry for the treatment of hepatitis C virus infections. It is also being explored for potential applications in other fields such as polymer science and materials science, though its main commercial use is in drug development.

When handling Pibrentasvir, it is crucial to use personal protective equipment (PPE) such as gloves, goggles, and a lab coat. Work should be performed in a well-ventilated fume hood. Spills should be cleaned up using appropriate absorbent materials and disposed of according to laboratory waste procedures. Always consult the Safety Data Sheet (SDS) for detailed handling instructions.